Efficacy and safety of botulinum neurotoxin NT 201 in poststroke upper limb spasticity

Clinical Neuropharmacology

Volumn 32, Issue 5, 2009, Pages 259-265

  Kaňovský, Petr ^a   Slawek, Jaroslaw ^b,c   Denes, Zoltan ^d   Platz, Thomas ^e   Sassin, Irena ^f   Comes, Georg ^f   Grafe, Susanne ^f  

^a PALACKÝ UNIVERSITY   (Czech Republic)

^b Lekarski Gabinet Zabiegowy URO ^*

^c MEDICAL UNIVERSITY OF GDANSK   (Poland)

^d National Institute for Medical Rehabilitation   (Hungary)

^e UNIVERSITY OF GREIFSWALD   (Germany)

^f MERZ PHARMACEUTICALS GMBH   (Germany)

Author keywords

Botulinum toxin type A; NT 201; Stroke; Upper limb spasticity

Indexed keywords

BOTULINUM TOXIN A;

ADULT; AGED; ARTICLE; CAREGIVER BURDEN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONTUSION; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DYSESTHESIA; DYSPHAGIA; EPILEPSY; FEELING HOT; FEMALE; FINGER; FLEXOR MUSCLE; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPESTHESIA; INJECTION SITE HEMATOMA; INJECTION SITE PAIN; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; MUSCLE TONE; PARAPLEGIA; PHYSICAL DISABILITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SENSORY DYSFUNCTION; SPASTICITY; UPPER LIMB SPASTICITY; VOMITING; WRIST;

ADULT; AGED; ARM; BOTULINUM TOXIN TYPE A; DOUBLE-BLIND METHOD; FEMALE; HEADACHE; HUMANS; MALE; MIDDLE AGED; MUSCLE SPASTICITY; PAIN; STROKE;

EID: 70349789692     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/WNF.0b013e3181b13308     Document Type: Article

References (27)

1. Lance JW. Symposium synopsis. In: Feldman RG, Young RR, Koella WP, eds. Spasticity, Disordered Motor Control. Miami, Fla: Symposia Specialists; 1980:485-494.
2. Lundström E, Terént A, Borg J. Prevalence of disabling spasticity 1 year after first-ever stroke. Eur J Neurol 2008;15:533-539.
3. Ozcakir S, Sivrioglu K. Botulinum toxin in poststroke spasticity. Clin Med Res 2007;5:132-138.
4. Wissel J, Mü ller J, Dressnandt J, et al. Management of spasticity associated pain with botulinum toxin A. J Pain Symptom Manage 2000;20:44-49.
5. Gelber DA. Management of stroke related spasticity in the long-term care setting. Pharmacy Practice News 2003;30:53-57.
6. Simpson DM, Gracies J-M, Yablon S, et al. Botulinum neurotoxin vs tizanidine in upper limb spasticity: a placebo-controlled study. J Neurol Neurosurg Psychiatry 2009;80:380-385. doi: 10.1136/jnnp.2008.159657.
7. Rosales RL, Chua-Yap AS. Evidence-based systematic review on the efficacy and safety of botulinum toxin-A therapy in post-stroke spasticity. J Neural Transm 2008;115:617-623.
8. Simpson DM, Gracies J-M, Graham HK, et al. Assessment: botulinum neurotoxin for the treatment of spasticity (an evidence-based review). Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008;70:1691-1698.
9. Blümel J, Frevert J, Schwaier A. Comparative antigenicity of three preparations of botulinum neurotoxin type A in the rabbit. Neurotoxicity Res 2006;9:238(abstract).
10. Benecke R, Jost WH, Kanovsky P, et al. A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia. Neurology 2005;64:1949-1951.
11. Roggenkämper P, Jost WH, Bihari K, et al. Efficacy and safety of a new botulinum toxin type A free of complexing proteins in the treatment of blepharospasm. J Neural Transm 2006;113: 303-312.
12. Ashworth B. Preliminary trial of carisoprodol in multiple sclerosis. Practitioner 1964;192:540-542.
13. Brashear A, Zafonte R, Corcoran M, et al. Inter- and intra-rater reliability of the Ashworth Scale and the Disability Assessment Scale in patients with upper-limb poststroke spasticity. Arch Phys Med Rehabil 2002;83:1349-1354.
14. Jost WH, Blümel J, Grafe S. Botulinum neurotoxin type A free of complexing proteins (XEOMIN\) in focal dystonia. Drugs 2007;67:669-683. (Pubitemid 46535642)
15. WE MOVE. BTX-A (BOTOX\) Adult Dosing Guidelines for the Management of Spasticity. Aug 2005. Available at: http:// www.mdvu.org/library/dosingtables/. Accessed September 2005.
16. Albright AL, Barron WB, Fasick MP, et al. Continuous intrathecal baclofen infusion for spasticity of cerebral origin. JAMA 1993;270:2475-2477.
17. Brashear A, Gordon MF, Elovic E, et al. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N Engl J Med 2002;347:395-400.
18. Platz T, Vuadens P, Eickhof C, et al. REPAS, a summary rating scale for resistance to passive movement: item selection, reliability and validity. Disabil Rehabil 2008;30:44-53.
19. Bhakta BB, Cozens JA, Chamberlain MA, et al. Impact of botulinum toxin type A on disability and carer burden due to arm spasticity after stroke: a randomised double blind placebo controlled trial. J Neurol Neurosurg Psychiatry 2000;69:217-221.
20. Göschel H, Wohlfarth K, Frevert J, et al. Botulinum A toxin therapy: neutralizing and nonneutralizing antibodiesVtherapeutic consequences. Exp Neurol 1997;147:96-102.
21. Simpson DM, Alexander DN, O'Brien CF, et al. Botulinum toxin type A in the treatment of upper extremity spasticity: a randomized, double-blind, placebo-controlled trial. Neurology 1996;46:1306-1310.
22. Smith SJ, Ellis E, White S, et al. A double-blind, placebo-controlled study of botulinum toxin in upper limb spasticity after stroke or head injury. Clin Rehabil 2000;14:5-13.
23. BakheitAMO, Thilmann AF,Ward AB, et al. A randomized, double-blind, placebo-controlled, dose-ranging study to compare the efficacy and safety of three doses of botulinum toxin type A (Dysport) with placebo in upper limb spasticity after stroke. Stroke 2000;31:2402-2406.
24. Bakheit AMO, Pittock S, Moore AP, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of botulinum toxin type A in upper limb spasticity in patients with stroke. Eur J Neurol 2001;8:559-565.
25. Childers MK, Brashear A, Jozefczyk P, et al. Dose-dependent response to intramuscular botulinum toxin type A for upper-limb spasticity in patients after a stroke. Arch Phys Med Rehabil 2004;85:1063-1069.
26. Jost WH, Kohl A, Brinkmann S, et al. Efficacy and tolerability of a botulinum toxin type A free of complexing proteins (NT 201) compared with commercially available botulinum toxin type A (BOTOX\) in healthy volunteers. J Neural Transm 2005;112: 905-913.
27. Wohlfarth K, Mü ller C, Sassin I, et al. Neurophysiological double-blind trial of a botulinum neurotoxin type A free of complexing proteins. Clin Neuropharmacol 2007;30:86-94.